Johnson & Johnson Leverages AI and Robotics to Target $100 Billion Annual Revenue

Johnson & Johnson expects to surpass $100 billion in annual revenue this year for the first time in its 140-year history, according to Chairman and CEO Joaquin Duato.

During the second quarter, Johnson & Johnson reported operational sales growth of 5.6%, totaling $25.3 billion. The Innovative Medicine business grew 6.8% to reach $16.4 billion, while the MedTech business increased 3.6% to $8.9 billion, according to the company’s earnings release.

AI and Robotic Surgical Integration

The company is integrating artificial intelligence and robotics into its medical technology portfolio to drive future growth. In April, Johnson & Johnson launched Cartosound Sonata, an AI-based imaging and mapping tool for electrophysiology. The system uses AI to create maps that allow physicians to build accurate models of multiple heart chambers and treat heart rhythm conditions.

Duato stated during the July 15 call that the AI tool strengthens the company’s MedTech position. He also provided an update on Ottava, a table-integrated robotic surgical system currently progressing toward potential FDA authorization.

In surgery, we are unlocking a new era powered by robotics and digital innovation. [Ottava] is one of the most significant MedTech innovations we will bring to market this decade.

Bladder Cancer Treatment and FDA Approvals

Johnson & Johnson is monitoring the market performance of Inlexzo, a drug-releasing system designed for the local delivery of cancer medication into the bladder. The system received FDA approval in September 2025.

In a press release issued at the time of approval, the company described the system as a potential practice-changing treatment for specific patient groups. During the July 15 earnings call, Duato noted that the company is encouraged by the early momentum of Inlexzo sales.

Strategic Outlook and Revenue Targets

The push toward the $100 billion revenue milestone relies on a combination of pharmaceutical medicines and next-generation medical devices. The company’s current operational growth is distributed across its two primary business segments: Innovative Medicine and MedTech.

Our progress in Q2 reflects what makes Johnson & Johnson unique, a company innovating across the full spectrum of healthcare, delivering strong performance today while building a pipeline that will transform care for patients tomorrow.

Duato added that the company’s confidence in these targets is rooted in the breadth of its innovation pipeline, ranging from transformational medicines to digital health technologies.